(CBS/AP) The FDA moved closer to approving Xarelto (rivaroxaban) for the treatment of a heart condition that raises the risk for stroke when an advisory panel for the agency on Thursday green ...

Giving the anti-clotting drug rivaroxaban to patients for 12 weeks instead of the usual six after a blood clot in the lower leg reduces the risk of further clots developing up to two years after ...

FDA approves two new indications for Xarelto ® (rivaroxaban) to help prevent and treat blood clots in pediatric patients. News release. Janssen Pharmaceutical Companies of Johnson & Johnson.

Anti-clotting drug significantly reduces bleeding events in patients with ... the team found that both doses of abelacimab almost eliminated gastrointestinal bleeding compared to rivaroxaban, ...

Patients need to be tested regularly to be sure their blood is clotting at the safest level -- too much and a stroke can happen, not enough clotting and bleeding risks go up.

The anti-clotting drug rivaroxaban helps lower the risk of heart attack, stroke and death in patients who are hospitalized for a heart attack or chest pain, according to a study released Sunday ...

June 18 -- WEDNESDAY, June 17 (HealthDay News) -- The new anti-clotting pill rivaroxaban (Xarelto) lowers the risk of stroke, heart attack and death in patients who have had a heart attack or ...

Learn about side effects, dosage, and more for Xarelto (rivaroxaban), ... This type of drug works to decrease blood clotting. Xarelto comes as a tablet that you take by mouth.

Table 1. The Regulation of Coagulation in Major Orthopedic Surgery Reducing the Risk of DVT and PE (RECORD) program. Study Procedure Patients randomized (n) Duration of therapy Ref. Rivaroxaban ...

Giving the anti-clotting drug rivaroxaban to patients for 12 weeks instead of the usual six after a blood clot in the lower leg reduces the risk of further clots developing up to two years after ...

*First dose initiated 12 h before surgery and reinitiated 6–8 h after wound closure; dosing regimen 40 mg once daily. ‡First dose 12–24 h after wound closure; dosing regimen 30 mg twice ...